Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biodefense tests

This article was originally published in The Gray Sheet

Executive Summary

Purchasing rapid, point-of-care tests for diagnosing bioterrorism agents such as anthrax, small pox and plague are among "mid-term" priorities of HHS' "public health medical countermeasures enterprise implementation plan," issued April 23 in the Federal Register. The agency plans to purchase up to $100 million worth of diagnostics from 2009-2013 using funds authorized by the Project BioShield Act of 2004, which allows the government to contract for emergency countermeasure products that would normally not have a market. Current BioShield funding is focused on vaccines for anthrax and small pox and treatments for radiation sickness...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT024733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel